Salmen Teodor, Rizvi Ali Abbas, Rizzo Manfredi, Pietrosel Valeria-Anca, Bica Ioana-Cristina, Diaconu Cosmina Theodora, Potcovaru Claudia Gabriela, Salmen Bianca-Margareta, Coman Oana Andreia, Bobircă Anca, Stoica Roxana-Adriana, Pantea Stoian Anca
Doctoral School of Carol Davila, University of Medicine and Pharmacy, 020021 Bucharest, Romania.
Department of Medicine, University of Central Florida College of Medicine, Orlando, FL 32827, USA.
Biomedicines. 2023 Sep 4;11(9):2455. doi: 10.3390/biomedicines11092455.
In this paper, we aim to evaluate the efficacy of antidiabetic cardioprotective molecules such as Sodium-Glucose Cotransporter-2 Inhibitors (SGLT-2i) and Glucagon-like Peptide 1 Receptor Agonists (GLP-1 RAs) when used with other glucose-lowering drugs, lipid-lowering, and blood pressure (BP)-lowering drugs in a real-life setting. A retrospective, observational study on 477 patients admitted consecutively in 2019 to the outpatient clinic of a tertiary care unit for Diabetes Mellitus was conducted. Body mass index (BMI), blood pressure (BP) (both systolic and diastolic), and metabolic parameters, as well as A1c hemoglobin, fasting glycaemia and lipid profile, including total cholesterol (C), HDL-C, LDL-C and triglycerides), were evaluated at baseline and two follow-up visits were scheduled (6 months and 12 months) in order to assess the antidiabetic medication efficacy. Both SGLT-2i and GLP-1 RAs were efficient in terms of weight control reflected by BMI; metabolic control suggested by fasting glycaemia and A1c; and the diastolic component of BP control when comparing the data from the 6 and 12-month visits to the baseline, and when comparing the 12-month visit to the 6-month visit. Moreover, when comparing SGLT-2i and GLP-1 RAs with metformin, there are efficacy data for SGLT-2i at baseline in terms of BMI, fasting glycaemia, and HbA1c. In this retrospective study, both classes of cardioprotective molecules, when used in conjunction with other glucose-lowering, antihypertensive, and lipid-lowering medications, appeared to be efficient in a real-life setting for the management of T2DM.
在本文中，我们旨在评估抗糖尿病心脏保护分子，如钠-葡萄糖协同转运蛋白2抑制剂（SGLT-2i）和胰高血糖素样肽1受体激动剂（GLP-1 RAs），与其他降糖药、降脂药和降压药联合使用时在实际临床环境中的疗效。我们对2019年连续入住一家三级医疗单位糖尿病门诊的477例患者进行了一项回顾性观察研究。在基线时评估了体重指数（BMI）、血压（收缩压和舒张压）、代谢参数，以及糖化血红蛋白A1c、空腹血糖和血脂谱，包括总胆固醇（C）、高密度脂蛋白胆固醇（HDL-C）、低密度脂蛋白胆固醇（LDL-C）和甘油三酯），并安排了两次随访（6个月和12个月）以评估抗糖尿病药物的疗效。当比较来自6个月和12个月随访的数据与基线数据，以及比较12个月随访与6个月随访的数据时，SGLT-2i和GLP-1 RAs在BMI反映的体重控制、空腹血糖和糖化血红蛋白A1c提示的代谢控制以及血压控制的舒张压成分方面均有效。此外，当将SGLT-2i和GLP-1 RAs与二甲双胍进行比较时，SGLT-2i在基线时在BMI、空腹血糖和糖化血红蛋白A1c方面有疗效数据。在这项回顾性研究中，这两类心脏保护分子与其他降糖、降压和降脂药物联合使用时，在实际临床环境中似乎对2型糖尿病的管理是有效的。
